Navigation Links
Cynosure to Announce Second-Quarter 2008 Financial Results on July 29

WESTFORD, Mass., July 15 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced that the company will host its second-quarter 2008 conference call on Tuesday, July 29, 2008 at 9:00 a.m. ET.

On the call, President and Chief Executive Officer Michael Davin and Executive Vice President and Chief Financial Officer Timothy Baker will discuss Cynosure's second-quarter financial results, as well as the company's business outlook and growth strategy.

Those who wish to listen to the conference call webcast should visit the "Investor Relations" section of the company's website at The live call also can be accessed by dialing (877) 407-5790 or (201) 689-8328. If you are unable to listen to the live call, the webcast will be archived on the company's website.

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.

For corporate or product information, contact Cynosure at 800-886-2966, or visit


Scott Solomon

Vice President

Sharon Merrill Associates, Inc.


SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cynosure President and CEO Michael Davin Named Ernst & Young Entrepreneur of the Year(R) 2008 Award Winner in New England
2. Cynosure Expands Presence in China with the Opening of Sales Office in Beijing
3. Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference
4. Cynosures Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
5. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
6. Cynosure Launches Three Aesthetic Products at American Academy of Dermatology 2008 Annual Meeting
7. CoolTouch Inc. Responds to Cynosure Patent Infringement Lawsuit
8. Cynosure Files Patent Infringement Lawsuit Against CoolTouch Inc.
9. Cynosure to Announce Third-Quarter 2007 Financial Results on November 1
10. Cynosure to Present at the Maxim Group Growth Conference
11. Retirement Living TV Announces Series Premiere of Viewpoint with Lea Thompson on July 18, 2008
Post Your Comments:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: